
According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65 million in sales, a 1195.47% increase since Q3. In Q3, Regenxbio brought in $30.77 million in sales but lost $58.41 million in earnings.